Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: DePuy

This article was originally published in The Gray Sheet

Executive Summary

DePuy: Gains FDA approval for its Endurance polymethylmethacrylate bone cement, which is intended for use "to fix joint reconstructive implants, primarily hips and knees, in the replacement of worn or damaged joints," the Warsaw, Indiana firm explains. Separately, DePuy says it plans to commence Phase I clinical trials by year-end of its SIS product, derived from the small-intestinal submucosa of pigs, for replacement of ruptured anterior cruciate ligaments of the knee. The initial studies will include 12 patients to be treated at two U.S. sites...



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts